-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options

Sponsor: Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), Diseases, Therapies, Adverse Events, Biological Processes, Minimal Residual Disease
Friday, December 8, 2023: 7:00 AM-10:00 AM
Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)
Nikhil C. Munshi, MD, Jerome Lipper Multiple Myeloma Center, Harvard Medical School
Munshi: Bristol Myers Squibb: Consultancy; GlaxoSmithKline: Consultancy; AbbVie: Consultancy; Adaptive Biotechnologies: Consultancy; Janssen: Consultancy; Karyopharm: Consultancy; Legend: Consultancy; Novartis: Consultancy; OncoPep: Consultancy; Pfizer: Consultancy, Current holder of stock options in a privately-held company; Takeda: Consultancy.
Hans Lee, MD, The University of Texas MD Anderson Cancer Center , Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Sorbonne University and Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center
Lee: Bristol Myers Squibb: Consultancy, Research Funding; Genentech: Consultancy; GlaxoSmithKline: Consultancy, Research Funding; Sanofi: Consultancy; Pfizer: Consultancy; Monte Rosa Therapeutics: Consultancy; Takeda Pharmaceuticals: Consultancy, Research Funding; Allogene Thereapeutics: Consultancy; Regeneron: Consultancy, Research Funding; Amgen: Research Funding; Janssen: Consultancy, Research Funding; Celgene: Consultancy; AbbVie: Consultancy. Mohty: JAZZ PHARMACEUTICALS: Honoraria, Research Funding. Patel: Takeda: Consultancy; AbbVie; Arcellx, AstraZeneca; Bristol Myers Squibb/Celgene Corporation; Caribou Science; Cellectis; Curio Bioscience; Genentech; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; Precision BioSciences: Consultancy; AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb/Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.: Research Funding.
On Demand program will be available here December 13, 2023.

This CME/MOC/AAPA activity is provided by PVI, PeerView Institute for Medical Education, and developed with our educational partner HealthTree Foundation for Multiple Myeloma.

This activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.

A new therapeutic standard has been raised in multiple myeloma (MM). In the wake of successes with CD38 antibody platforms, it became clear that as patients were increasingly treated with a greater number of active agents, strategies with unique mechanisms of action were required for patients exposed to multiple lines of modern therapy. Enter the BCMA options, including antibody-drug conjugates, bispecific antibodies, and cellular therapy.

This symposium will take the story from there and offer expert-led, case-centered discussion on the major themes of treatment selection, sequencing across lines of therapy, and unique AE management that have emerged as new BCMA standards enter the clinic. Our experts will close each scientific segment by sharing resources from the HealthTree Foundation for Multiple Myeloma to support the real-world application of anti-BCMA platforms across the continuum of myeloma patient care. Join the experts in raising new standards of care for your patients with MM!